Cardiovascular Today—June 11, 2026

LucidQuest

8 hours ago

This week’s Cardiovascular-weekly video recap update highlights regulatory milestones, device innovation, imaging standardization, digital surgery advances, financing activity, and emerging real-world safety findings in cardiovascular care.

In Today’s Newsletter

Dive deeper

💰 Advanced NanoTherapies raises Series B for dual-drug balloon platform [1] [03 Jun 2026]

https://cardiovascularnews.com/advanced-nanotherapies-secures-over-us31-million-series-b-to-deliver-dual-drug-nanoparticle-coated-balloon-platform/
Context: Advanced NanoTherapies (ANT) is developing SirPlux Duo, a dual-drug (paclitaxel and sirolimus) nanoparticle-coated balloon platform licensed from Cleveland Clinic.
Key point: ANT announced an oversubscribed Series B financing round to support manufacturing scale-up, FDA submissions, and pivotal study preparation.
Implication: Signals pipeline investment and modality expansion.

🫀 Edwards gains FDA clearance for dedicated tricuspid valve [2] [US • 04 Jun 2026]

https://cardiovascularbusiness.com/topics/clinical/tricuspid-valve/fda-clears-first-dedicated-tricuspid-surgical-valve
Context: Triformis Resilia is designed specifically for tricuspid valve replacement and uses Edwards’ Resilia tissue technology.
Key point: FDA cleared the first surgical tricuspid valve purpose-built for patients with tricuspid valve disease.
Implication: May influence prescriber choice and payer reviews pending full data.

📊 SCCT and SCAI publish CT-FFR consensus guidance [3] [04 Jun 2026]

https://cardiovascularbusiness.com/topics/cardiac-imaging/computed-tomography-ct/ct-ffr-standardized-new-scct-scai-consensus-statement
Context: The guidance was developed by SCCT and SCAI and endorsed by the American College of Cardiology (ACC).
Key point: The consensus document standardizes acquisition, interpretation, and reporting practices for CT-derived fractional flow reserve (FFR-CT).
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🔬 Plaque imaging and AI headline SCCT 2026 agenda [4] [04 Jun 2026]

https://cardiovascularbusiness.com/topics/professional-associations/cardiology-associations/scct/plaque-imaging-ai-and-structural-heart-disease-spotlight-scct-2026-meeting
Context: SCCT’s annual meeting will include sessions on plaque imaging, AI, CT-FFR, photon-counting CT, and structural heart imaging.
Key point: Society leaders highlighted advanced plaque analysis and AI as major themes shaping future cardiac CT practice.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

⚡ First U.S. implant of Biotronik LivIQ leadless pacemaker [5] [US • 08 Jun 2026]

https://cardiovascularbusiness.com/topics/cardiac-imaging/ep-lab/first-us-patient-implanted-biotronik-leadless-pacemaker
Context: LivIQ is an investigational leadless pacemaker designed to provide AV synchrony using atrial far-field sensing.
Key point: The first U.S. patient was implanted as part of the BIO-LivIQ global pivotal trial.
Implication: May influence prescriber choice and payer reviews pending full data.

🌍 Robotic cardiac telesurgery completed across 12,500 miles [6] [Guyana • 08 Jun 2026]

https://cardiovascularbusiness.com/topics/clinical/cardiac-surgery/longest-distance-robotic-cardiac-telesurgery-ever-performed-over-12500-miles
Context: The procedure connected a surgeon in Guyana with a patient in India using the SSi Mantra robotic system.
Key point: SS Innovations reported the longest-distance robotic cardiac telesurgery performed to date.
Implication: May expand screening, initiation, and follow-up at scale.

🏥 MedTech Dive coverage of Edwards tricuspid approval [7] [US • 03 Jun 2026]

https://www.medtechdive.com/news/edwards-gets-fda-approval-for-surgical-tricuspid-valve/821949/
Context: The report highlights the unmet need in tricuspid valve disease treatment.
Key point: FDA approval expands Edwards Lifesciences’ Resilia tissue technology into the tricuspid position.
Implication: Introduces competition that may affect pricing and formulary access.

📈 Infective endocarditis in pregnancy linked to higher maternal risk [8] [US • 09 Jun 2026]

https://www.thecardiologyadvisor.com/news/infective-endocarditis-pregnancy-cardiovascular-complications/
Context: Retrospective observational analysis of U.S. delivery hospitalizations from 2011–2020.
Key point: Infective endocarditis during pregnancy was associated with increased risks of acute kidney injury, stroke, venous thromboembolism, arrhythmias, and in-hospital mortality.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
Why it matters

Tricuspid valve disease continues to gain attention, with dedicated surgical devices reaching the U.S. market. [2][7]
Cardiac CT is evolving from anatomical imaging toward physiology, plaque characterization, and AI-enabled decision support. [3][4]
Leadless pacing remains a competitive innovation area, with new entrants pursuing AV-synchronous solutions. [5]
Robotic telesurgery is progressing from proof-of-concept toward broader global access models. [6]
Pregnancy-related cardiovascular complications remain an important area for risk identification and care coordination. [8]

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Cardiovascular archive on our research hub page

FAQ

What is SirPlux Duo from Advanced NanoTherapies?

SirPlux Duo is ANT’s lead dual-drug nanoparticle-coated balloon program combining paclitaxel and sirolimus. The program has FDA Breakthrough Device designation. [1]

What makes Edwards’ Triformis Resilia notable?

It is the first surgical tricuspid valve specifically designed for tricuspid valve replacement rather than adapted from another valve position. [2][7]

What is CT-FFR used for?

CT-derived fractional flow reserve estimates the physiologic impact of coronary lesions using coronary CT angiography data and may help guide revascularization decisions. [3]

What is Biotronik evaluating in the BIO-LivIQ study?

The pivotal trial is assessing safety, pacing efficacy, AV synchrony behavior, and quality-of-life outcomes for the investigational LivIQ leadless pacemaker. [5]

Why is the Guyana–India telesurgery procedure significant?

SS Innovations reported it as the longest-distance robotic cardiac telesurgery completed to date, demonstrating remote surgical capabilities across continents. [6]

What did the pregnancy infective endocarditis study find?

The observational analysis found associations between infective endocarditis and higher risks of several serious maternal complications, including stroke, acute kidney injury, and in-hospital mortality. [8]

Entities / Keywords

Advanced NanoTherapies (ANT), SirPlux Duo, drug-coated balloon (DCB), paclitaxel, sirolimus
Edwards Lifesciences, Triformis Resilia, Resilia tissue technology, tricuspid valve disease
SCCT, SCAI, ACC, FFR-CT, CCTA, cardiac CT
Biotronik, LivIQ, BIO-LivIQ, leadless pacemaker, AV synchrony
SS Innovations, SSi Mantra, robotic telesurgery, cardiac surgery
Infective Endocarditis (IE), pregnancy, acute kidney injury (AKI), stroke, maternal outcomes